Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 5.3 %

NASDAQ:AKTX opened at $1.38 on Friday. The business’s 50-day moving average price is $1.51 and its 200 day moving average price is $2.65. Akari Therapeutics has a 52-week low of $0.90 and a 52-week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.